Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
1.19 M
Value Traded
14.19 M
Short % Float
10.66%
-6.84%Week
-25.75%1 Month
-10.23%3 Month
-15.03%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.32 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
2.20 B
Total Shares
123.53 M
Float Shares
77.48 M
Insiders
37.28%
Institutions
50.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PBLS Catalyst Timeline
Dated clinical, regulatory and corporate events for Parabilis Medicines, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Parabilis Medicines, Inc. Common Stock
17Total events
7Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 8
▲Partnership / LicenseCorporate
Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates
●Management ChangeCorporate
Appointed Helen Ho as Chief Business & Strategy Officer and Tom Kotarakos as Chief Financial Officer
▲PublicationzolucatetidePresentation
Correspondence published in NEJM demonstrating durable response in recurrent ameloblastoma
ameloblastomasource ↗
▲PublicationzolucatetidePresentation
Correspondence published in NEJM demonstrating durable response in recurrent ameloblastoma
ameloblastomasource ↗
Past FDA Catalysts and PDUFA Decisions
How PBLS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every PBLS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Director, 10% Owner | Buy | 47,250 26,529,686 held | $29.77 | 07/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PBLS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PBLS for Q2 2026. | ||||
PBLS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PBLS ranks across every disease it competes in
Competitive Position is a premium feature
See how PBLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPBLS News
-PBLS
Oct 14, 2026▼ -7.2%today
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Parabilis Medicines has initiated a dose-ranging clinical study of zolucatetide for familial adenomatous polyposis (FAP) as part of its ongoing Phase 1/2 trial. Zolucatetide, a direct inhibitor of the β-catenin:TCF interaction, has shown promising early results in reducing precancerous polyp burden in patients. The study aims to evaluate zolucatetide's efficacy and define dosing for future registrational development.
Read more →-PBLS
Sep 1, 2026Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Parabilis Medicines will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. CEO Mathai Mammen will lead a fireside chat, discussing the company's innovative approaches to drug development. Parabilis focuses on creating therapies for serious diseases by targeting previously undruggable proteins. The event will be accessible via a live audio webcast.
Read more →-PBLS
Aug 25, 2026Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines has appointed Dr. Craig L. Tendler to its Board of Directors. Dr. Tendler brings over 30 years of experience in oncology drug development, having previously led clinical development at Johnson & Johnson. His expertise is expected to significantly contribute to the advancement of Parabilis' lead investigational medicine, zolucatetide, and its broader therapeutic pipeline.
Read more →-PBLS
Aug 13, 2026Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Parabilis Medicines reported its second-quarter financial results, highlighting advancements in zolucatetide for treating Wnt/β-catenin-driven diseases, particularly desmoid tumors. The company announced a strategic collaboration with Regeneron, potentially worth $2.2 billion, and ended the quarter with a robust cash position of $1.1 billion. Despite a net loss of $52.5 million, the company remains optimistic about its clinical and regulatory milestones.
Read more →-PBLS
Jun 11, 2026Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Parabilis Medicines, Inc. has successfully closed its upsized initial public offering, raising $770.5 million through the sale of 38,525,000 shares at $20.00 each. The offering included a full exercise of the underwriters' option to purchase additional shares. Additionally, Parabilis secured $75 million from a concurrent private placement with Regeneron Pharmaceuticals. The company aims to develop transformative medicines targeting historically undruggable proteins.
Read more →-PBLS
Jun 10, 2026Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
Parabilis Medicines, Inc. has announced the pricing of its upsized initial public offering, offering 33.5 million shares at $20.00 each. The IPO is expected to raise around $670 million and will close on or about June 11, 2026. Additionally, a concurrent private placement with Regeneron Pharmaceuticals will provide approximately $75 million.
Read more →-PBLS
May 18, 2026Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines has announced a strategic collaboration with Regeneron Pharmaceuticals to develop novel Antibody-Helicon™ Conjugates targeting difficult-to-drug proteins. The agreement includes a $125 million investment from Regeneron, with potential milestone payments reaching approximately $2.2 billion. This partnership aims to leverage Parabilis's Helicon™ peptide platform alongside Regeneron's antibody expertise.
Read more →-PBLS
May 7, 2026Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors
Parabilis Medicines has appointed Alan M. Sebulsky to its Board of Directors. Sebulsky, a seasoned biopharmaceutical finance leader, brings extensive experience in public company investment and financial strategy. His background includes leadership roles in significant healthcare firms, enhancing Parabilis's capacity to advance its innovative peptide platform and cancer therapies.
Read more →-PBLS
Apr 14, 2026Parabilis Medicines Expands Executive Leadership Team
Parabilis Medicines has announced the expansion of its executive leadership team with the appointment of Helen Ho, Ph.D. as Chief Business and Strategy Officer. This move aims to enhance the company's corporate growth strategy and business development efforts. Additionally, Thomas Kotarakos has been promoted to Chief Financial Officer to support the company's financial strategy.
Read more →-PBLS
Mar 11, 2026Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors
Parabilis Medicines announced that zolucatetide has received FDA Orphan Drug Designation for treating desmoid tumors. This investigational drug is the first direct inhibitor of the β-catenin:TCF interaction, addressing a previously undruggable target. Early clinical data indicates significant antitumor activity, with plans for further trials underway.
Read more →-PBLS
Mar 5, 2026Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
Parabilis Medicines has reported early clinical evidence from its ongoing Phase 1/2 trial of zolucatetide, showing significant reductions in duodenal polyposis and a decrease in the size of a co-existing desmoid tumor. This data was presented at the InSiGHT Biennial Meeting, highlighting the potential effectiveness of zolucatetide in treating patients with Familial Adenomatous Polyposis.
Read more →About Parabilis Medicines, Inc. Common Stock
Headquarters30 ACORN PARK DRIVE, CAMBRIDGE, MA, 02140
BIOPHARMAWATCH ELITE PLUS
Trade the next PBLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime